Sema4 and GNS Healthcare Announce Collaboration Using REFS™ Causal Machine Learning and Simulation AI Platform

Working Towards New Therapies for Cardiovascular Disease Stamford, Conn. and Cambridge, Mass. – June 27, 2017– Sema4, an interdisciplinary health information company with expertise in collecting diverse data, building computational models of disease and unlocking solutions to disease, today announced it is leveraging GNS Healthcare’s (GNS), REFS™ (Reverse Engineering and Forward Simulation) causal machine learning […]

GNS Healthcare Announces Collaboration to Power Cancer Drug Development with REFS™ Causal Machine Learning and Simulation AI Platform

CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancer therapies. The GNS technology turns large and diverse […]